Skip to main content
TipRanks
Go Ultimate75% OFF

Nabriva Therapeutics (NBRVF) Ratios

1,010 Followers

Nabriva Therapeutics Ratios

NBRVF's free cash flow for Q2 2023 was $511.00K. For the 2023 fiscal year, NBRVF's free cash flow was decreased by $-22.00 and operating cash flow was $511.00K. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 22Dec 21Dec 20Dec 19Dec 18
Liquidity Ratios
Current Ratio1.133.593.095.486.11
Quick Ratio0.782.942.775.446.11
Cash Ratio0.452.132.235.175.73
Solvency Ratio-2.00-1.77-2.71-1.55-2.73
Operating Cash Flow Ratio-1.33-2.67-3.85-4.32-4.08
Short-Term Operating Cash Flow Coverage-7.60-15.82-34.950.000.00
Net Current Asset Value$ 2.63M$ 52.71M$ 31.92M$ 38.33M$ 66.97M
Leverage Ratios
Debt-to-Assets Ratio0.160.100.130.370.21
Debt-to-Equity Ratio1.590.150.230.840.35
Debt-to-Capital Ratio0.610.130.190.460.26
Long-Term Debt-to-Capital Ratio0.110.070.150.460.26
Financial Leverage Ratio9.651.521.762.281.61
Debt Service Coverage Ratio-10.17-10.27-17.75-21.63-858.17
Interest Coverage Ratio-79.50-53.86-38.11-21.81-859.96
Debt to Market Cap2.054.8715.83122.37122.88
Interest Debt Per Share2.215.1518.42128.53117.39
Net Debt to EBITDA0.130.840.500.650.69
Profitability Margins
Gross Profit Margin19.87%51.69%68.45%99.10%100.00%
EBIT Margin-153.97%-176.58%-1346.65%-1025.93%-1763.05%
EBITDA Margin-153.36%-174.24%-1330.34%-1015.99%-1755.20%
Operating Profit Margin-155.57%-178.31%-1315.42%-1025.93%-1759.62%
Pretax Profit Margin-155.93%-179.89%-1379.45%-1066.89%-1765.09%
Net Profit Margin-160.33%-181.69%-1382.22%-1068.20%-1765.85%
Continuous Operations Profit Margin-160.33%-181.69%-1382.22%-1068.20%-1765.85%
Net Income Per EBT102.82%101.00%100.20%100.12%100.04%
EBT Per EBIT100.23%100.89%104.87%103.99%100.31%
Return on Assets (ROA)-180.03%-61.12%-118.91%-87.94%-103.95%
Return on Equity (ROE)-1736.56%-92.69%-209.70%-200.52%-167.24%
Return on Capital Employed (ROCE)-1333.89%-82.86%-165.68%-102.60%-123.50%
Return on Invested Capital (ROIC)-617.04%-77.85%-157.62%-102.60%-123.50%
Return on Tangible Assets-180.04%-61.14%-119.07%-88.03%-104.04%
Earnings Yield-2244.40%-3001.88%-14235.20%-29353.40%-59464.15%
Efficiency Ratios
Receivables Turnover5.292.131.292.821.21
Payables Turnover5.263.010.550.010.00
Inventory Turnover2.950.910.270.100.00
Fixed Asset Turnover127.39116.816.553.135.71
Asset Turnover1.120.340.090.080.06
Working Capital Turnover Ratio1.160.560.090.090.08
Cash Conversion Cycle123.20452.42959.05-20680.95301.60
Days of Sales Outstanding68.99171.01283.82129.27301.60
Days of Inventory Outstanding123.57402.781340.103556.140.00
Days of Payables Outstanding69.36121.37664.8724366.360.00
Operating Cycle192.56573.791623.923685.41301.60
Cash Flow Ratios
Operating Cash Flow Per Share-13.69-34.35-138.83-242.23-357.92
Free Cash Flow Per Share-13.77-34.36-139.05-242.43-359.05
Dividend Paid and CapEx Coverage Ratio-173.99-2382.28-631.25-1178.56-317.57
Capital Expenditure Coverage Ratio-173.99-2382.28-631.25-1178.56-317.57
Operating Cash Flow Coverage Ratio-7.03-7.42-9.23-2.08-3.07
Operating Cash Flow to Sales Ratio-1.03-2.19-14.19-9.28-11.19
Free Cash Flow Yield-1449.11%-3616.95%-14636.75%-25519.13%-37794.29%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.04-0.03-0.01-0.00-0.00
Price-to-Sales (P/S) Ratio0.070.060.100.040.03
Price-to-Book (P/B) Ratio0.770.030.010.010.00
Price-to-Free Cash Flow (P/FCF) Ratio-0.07-0.03-0.01-0.00-0.00
Price-to-Operating Cash Flow Ratio-0.07-0.03-0.01-0.00-0.00
Price-to-Earnings Growth (PEG) Ratio0.000.000.000.000.00
Enterprise Value Multiple0.080.800.500.650.68
Enterprise Value-4.65M-37.98M-33.14M-51.24M-78.09M
EV to EBITDA0.080.800.500.650.68
EV to Sales-0.13-1.40-6.59-6.61-12.01
EV to Free Cash Flow0.130.640.460.711.07
EV to Operating Cash Flow0.130.640.460.711.07
Tangible Book Value Per Share1.2330.7564.33138.76311.34
Shareholders’ Equity Per Share1.2330.7764.49139.06337.77
Tax and Other Ratios
Effective Tax Rate-0.03-0.01-0.00-0.00-0.00
Revenue Per Share13.3015.709.7826.1131.99
Net Income Per Share-21.32-28.52-135.23-278.86-564.91
Tax Burden1.031.011.001.001.00
Interest Burden1.011.021.021.041.00
Research & Development to Revenue0.400.463.003.4112.66
SG&A to Revenue0.000.000.000.006.42
Stock-Based Compensation to Revenue0.060.121.041.260.00
Income Quality0.641.201.030.870.63

Currency in USD